Technical Insights on Biotech Stocks -- Idera Pharma, Pieris Pharma, Peregrine Pharma, and Ritter Pharma

Wednesday, July 5, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, July 5, 2017 /PRNewswire/ --

If you want a Stock Review on IDRA, PIRS, PPHM or RTTR then come over to

and sign up for your free customized report today. On Monday, benchmark US indices were in mixed colors as the NASDAQ Composite closed the trading session down 0.49%; the Dow Jones Industrial Average edged 0.61% higher; and the S&P 500 was up 0.23%.
US markets saw a mixed session as 4 sectors closed in green, 4 sectors finished in red, and 1 sector ended flat for the day. Pre-market today, reviews these four Biotechnology stocks: Idera Pharmaceuticals Inc. (NASDAQ: IDRA), Pieris Pharmaceuticals Inc. (NASDAQ: PIRS), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and Ritter Pharmaceuticals Inc. (NASDAQ: RTTR). Access's free research reports for this morning's stocks line-up at:

Idera Pharma 

Shares in Cambridge, Massachusetts-based Idera Pharmaceuticals Inc. ended Monday's session 1.74% higher at $1.75 with a total trading volume of 239,703 shares. The stock has advanced 1.74% in the last month and 16.67% on an YTD basis. The Company's shares are trading 4.65% below their 50-day moving average. Moreover, shares of Idera Pharma, which focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the US, have a Relative Strength Index (RSI) of 49.14. Free research report on IDRA is available at:

Pieris Pharma 

Boston, Massachusetts headquartered Pieris Pharmaceuticals Inc.'s shares rose 1.38%, closing the day at $5.13. A total volume of 467,008 shares were traded. The stock has advanced 4.91% in the last month, 99.61% in the previous three months, and 265.07% on an YTD basis. The Company's shares are trading 29.08% and 111.77% above their 50-day and 200-day moving averages, respectively. Additionally, shares of Pieris Pharma, which discovers and develops Anticalin-based drugs, have an RSI of 71.51. The complimentary research report on PIRS can be downloaded at:

Peregrine Pharma 

On Monday, shares in Tustin, California headquartered Peregrine Pharmaceuticals Inc. rose 0.36%, closing the session at $0.61. The stock recorded a trading volume of 433,576 shares. The Company's shares have advanced 2.55% in the last one month and 97.86% on an YTD basis. The stock is trading 4.72% above its 50-day moving average and 32.00% above its 200-day moving average. Furthermore, shares of Peregrine Pharma, which researches and develops monoclonal antibodies for the treatment of cancer in the US, have an RSI of 59.86. Visit us today and access our complete research report on PPHM at:

Ritter Pharma 

Los Angeles, California headquartered Ritter Pharmaceuticals Inc.'s stock finished the session 0.42% higher at $0.55. A total volume of 210,087 shares were traded. The Company's shares are trading below their 50-day moving average by 18.12%. Additionally, shares of Ritter Pharma, which develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, have an RSI of 38.21. Get free access to your research report on RTTR at:

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store